Literature DB >> 26433814

Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.

Robin Kate Kelley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26433814      PMCID： PMC4811670          DOI： 10.1016/S1470-2045(15)00296-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   54.433


× No keyword cloud information.
  9 in total

1.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

2.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

3.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Authors:  Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

Review 4.  Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.

Authors:  Giannis Mountzios; George Pentheroudakis; Peter Carmeliet
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

5.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

6.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M Llovet
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316

7.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Authors:  David Cameron; Julia Brown; Rebecca Dent; Christian Jackisch; John Mackey; Xavier Pivot; Guenther G Steger; Thomas M Suter; Masakazu Toi; Mahesh Parmar; Rita Laeufle; Young-Hyuck Im; Gilles Romieu; Vernon Harvey; Oleg Lipatov; Tadeusz Pienkowski; Paul Cottu; Arlene Chan; Seock-Ah Im; Peter S Hall; Lida Bubuteishvili-Pacaud; Volkmar Henschel; Regula J Deurloo; Celine Pallaud; Richard Bell
Journal:  Lancet Oncol       Date:  2013-08-07       Impact factor: 41.316

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Authors:  Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Erin B Kennedy; Ghassan Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; E Claire Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  9 in total
  10 in total

1.  Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.

Authors:  Jia Ding; Xiao-Tian Zhou; Hao-Yu Zou; Jian Wu
Journal:  Lab Invest       Date:  2017-04-17       Impact factor: 5.662

2.  Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.

Authors:  L X Xu; M H He; Z H Dai; J Yu; J G Wang; X C Li; B B Jiang; Z F Ke; T H Su; Z W Peng; Y Guo; Z B Chen; S L Chen; S Peng; M Kuang
Journal:  Ann Oncol       Date:  2019-06-01       Impact factor: 32.976

Review 3.  Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications.

Authors:  Di-Yang Xie; Hong-Kai Fan; Zheng-Gang Ren; Jia Fan; Qiang Gao
Journal:  Clin Transl Gastroenterol       Date:  2019-02       Impact factor: 4.488

4.  Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection.

Authors:  Qingli Li; Tianqiang Song
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

5.  Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma.

Authors:  Jian Hu; Feifei Mao; Lifang Li; Xiaoqian Wang; Depei Cai; Longmei He; Qian Wu; Cong Wang; Ning Zhang; Yanfen Ma; Xia Wu; Kai Qu; Xiaoqin Wang
Journal:  J Oncol       Date:  2022-03-29       Impact factor: 4.375

6.  The clonal expression genes associated with poor prognosis of liver cancer.

Authors:  Wanfeng Zhang; Fang Huang; Xia Tang; Longke Ran
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

7.  Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.

Authors:  Shiori Sugai; Toshiaki Yoshikawa; Tatsuaki Iwama; Nobuhiro Tsuchiya; Norihiro Ueda; Norihiro Fujinami; Manami Shimomura; Rong Zhang; Shin Kaneko; Yasushi Uemura; Tetsuya Nakatsura
Journal:  Int J Oncol       Date:  2016-02-19       Impact factor: 5.650

Review 8.  Targeted therapy for hepatocellular carcinoma.

Authors:  Ao Huang; Xin-Rong Yang; Wen-Yuan Chung; Ashley R Dennison; Jian Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-08-11

9.  Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.

Authors:  Wei Wei; Pei-En Jian; Shao-Hua Li; Zhi-Xing Guo; Yong-Fa Zhang; Yi-Hong Ling; Xiao-Jun Lin; Li Xu; Ming Shi; Lie Zheng; Min-Shan Chen; Rong-Ping Guo
Journal:  Cancer Commun (Lond)       Date:  2018-10-10

Review 10.  Emerging agents and regimens for hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2019-10-26       Impact factor: 17.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.